Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements
| Autor: | Aristides M. Tsatsakis, Nikolaos Drakoulis, Leda Kovatsi, V. M. Trukhan, Demetrios A. Spandidos, Luca Falzone, Charalampos Mamoulakis, Massimo Libra, Natalia O Tuaeva, Alexander E. Nosyrev, Yuri B. Porozov, Alexandra Kalogeraki, George N. Tzanakakis |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty diagnosis Review NGS biomarker ctDNA glioma liquid biopsy mass-spectrometry oncology prognosis urological cancers Circulating Tumor DNA 03 medical and health sciences 0302 clinical medicine Internal medicine Neoplasms medicine Biomarkers Tumor Mutational status Humans In patient Liquid biopsy lcsh:QH301-705.5 030304 developmental biology 0303 health sciences business.industry Cancer General Medicine Primary cancer medicine.disease Neoplastic Cells Circulating 3. Good health Biomarker (cell) lcsh:Biology (General) 030220 oncology & carcinogenesis Unknown primary Circulating DNA business Cell-Free Nucleic Acids |
| Zdroj: | Cells Cells, Vol 8, Iss 10, p 1251 (2019) |
| Popis: | In recent years, the introduction of new molecular techniques in experimental and clinical settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) analysis and liquid biopsy as novel promising strategies for the early diagnosis of cancer and for the definition of patients’ prognosis. It was widely demonstrated that through the non-invasive analysis of ctDNA, it is possible to identify and characterize the mutational status of tumors while avoiding invasive diagnostic strategies. Although a number of studies on ctDNA in patients’ samples significantly contributed to the improvement of oncology practice, some investigations generated conflicting data about the diagnostic and prognostic significance of ctDNA. Hence, to highlight the relevant achievements obtained so far in this field, a clearer description of the current methodologies used, as well as the obtained results, are strongly needed. On these bases, this review discusses the most relevant studies on ctDNA analysis in cancer, as well as the future directions and applications of liquid biopsy. In particular, special attention was paid to the early diagnosis of primary cancer, to the diagnosis of tumors with an unknown primary location, and finally to the prognosis of cancer patients. Furthermore, the current limitations of ctDNA-based approaches and possible strategies to overcome these limitations are presented. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|